UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                      Washington, D.C. 20549

                           FORM 10-KSB

[X]     ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
        EXCHANGE ACT OF 1934

           For the fiscal year ended December 31, 2001


[ ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
        AND    EXCHANGE ACT OF 1934

                 Commission file number 000-32363

                       CANCER CAPITAL CORP.
                       --------------------
      (Exact name of registrant as specified in its charter)

        Nevada                                         91-1803648
       --------                                       -----------
(State of incorporation)                (I.R.S. Employer Identification No.)


525 South 300 East, Salt Lake City, Utah                  84111
---------------------------------------                  -------
(Address of principal executive offices)                (Zip code)

Issuer's telephone number, including area code: (801) 323-2395

Securities registered pursuant to Section 12(b) of the Act: None.

Securities registered pursuant to Section 12(g) of the Act: Common Stock

The issuer (1) filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports) and
(2) has been subject to such filing requirements for the past 90 days.
Yes [X]  No [ ]

Disclosure of delinquent filers in response to item 405 of Regulation S-B is
not contained herein, and will not be contained, to the best of registrant's
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-KSB or any amendment to this Form
10-KSB.   [x]

State issuer's revenue for its most recent fiscal year: None.

A market value of the voting stock held by non-affiliates can not be
determined because the registrant does not have an active trading market.

As of February 27, 2002, the registrant had 5,150,000 shares of common stock
outstanding.

Documents incorporated by reference: None.

Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]



<PAGE>
                              PART I
Item 1.      Description of business ......................................2
Item 2.      Description of property ......................................6
Item 3.      Legal proceedings ............................................6
Item 4.      Submission of matters to a vote of security holders ..........6


                             PART II
Item 5.      Market for common equity and related stockholder matters .....7
Item 6.      Plan of operations ...........................................7
Item 7.      Financial statements .........................................7
Item 8.      Changes in and disagreements with accountants on
             accounting and financial disclosure..........................17

                             PART III
Item 9.      Directors and executive officers; Compliance with
             Section 16(a)................................................17
Item 10.     Executive compensation.......................................17
Item 11.     Security ownership of certain beneficial owners
             and management...............................................18
Item 12.     Certain relationships and related transactions...............19
Item 13.     Exhibits and reports on Form 8-K.............................19




                    FORWARD LOOKING STATEMENTS

     In this annual report references to "Cancer Capital," "we," "us," and
"our" refer to Cancer Capitol Corp.

     This annual report contains certain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.  For this
purpose any statements contained in this annual report that are not statements
of historical fact may be deemed to be forward-looking statements.  Without
limiting the foregoing, words such as "may," "will," "expect," "believe,"
"anticipate," "estimate" or "continue" or comparable terminology are intended
to identify forward-looking statements.  These statements by their nature
involve substantial risks and uncertainties, and actual results may differ
materially depending on a variety of factors, many of which are not within
Cancer Capital's control.  These factors include but are not limited to
economic conditions generally and in the industries in which Cancer Capital
may participate, competition within Cancer Capital's potential industry,
technological advances, and failure by Cancer Capital to successfully develop
business relationships.

                                2
<PAGE>

                              PART I

                 ITEM 1: DESCRIPTION OF BUSINESS

Business Development

     We were incorporated in the state of Nevada on April 11, 1997 to develop
an alternative medical waste treatment and processing equipment system.  We
were unsuccessful in our efforts and are inactive at this time.

Our Plan

     We are a "blank check" company and have had recurring operating losses
for the past two fiscal years.  Our independent auditors have expressed doubt
that we can continue as a going concern unless we obtain financing to continue
operations.

     Our business plan is to seek, investigate, and, if warranted, acquire an
interest in a business opportunity.  Our acquisition of a business opportunity
may be made by merger, exchange of stock, or otherwise.  We have very limited
sources of capital, and we probably will only be able to take advantage of one
business opportunity. At the present time we have not identified any business
opportunity that we plan to pursue, nor have we reached any preliminary or
definitive agreements or understandings with any person concerning an
acquisition or merger.

      Based on current economic and regulatory conditions, management believes
that it is possible, if not probable, for a company like ours, without many
assets or liabilities, to negotiate a merger or acquisition with a viable
private company.  The opportunity arises principally because of the high legal
and accounting fees and the length of time associated with the registration
process of "going public."  However, should any of these conditions change, it
is very possible that there would be little or no economic value for anyone
taking over control of Cancer Capital.

     Our search for a business opportunity will not be limited to any
particular geographical area or industry and includes both U.S. and
international companies.  Our management has unrestricted discretion in
seeking and participating in a business opportunity, subject to the
availability of such opportunities, economic conditions and other factors.
Our management believes that companies who desire a public market to enhance
liquidity for current stockholders or plan to acquire additional assets
through issuance of securities rather than for cash will be potential merger
or acquisition candidates.

     The selection of a business opportunity in which to participate is
complex and extremely risky and will be made by management in the exercise of
its business judgement.  There is no assurance that we will be able to
identify and acquire any business opportunity which will ultimately prove to
be beneficial to Cancer Capital and our stockholders.  Should a merger or
acquisition prove unsuccessful, it is possible management may decide not to
pursue further acquisition activities and management may abandon its
activities and we may become dormant or be dissolved.

     Our activities are subject to several significant risks which arise
primarily as a result of the fact that we have no specific business and may
acquire or participate in a business opportunity based on the decision of
management which will, in all probability, act without consent, vote, or
approval of our stockholders.

     It is possible that the range of business opportunities that might be
available for consideration by us could be limited by impact of the SEC
regulations regarding purchase and sale of "penny stock."  Our common stock is
not publicly traded at this time and we cannot assure that a market will
develop or that a stockholder ever will be able to liquidate his investments
without considerable delay, if at all.  If a market develops, our shares will
likely be subject to the rules of the Penny Stock Suitability Reform Act of
1990. The liquidity of penny stock is affected by specific disclosure
procedures required by this Act to be followed by all broker-dealers,
including but not limited to,


                                3
<PAGE>

determining the suitability of the stock for a particular customer, and
obtaining a written agreement from the customer to purchase the stock.  This
rule may affect the ability of broker-dealers to sell our securities and may
affect the ability of purchasers to sell our securities in any market.

Investigation and Selection of Business Opportunities

     We anticipate that business opportunities will come to our attention from
various sources, including our officers and directors, our stockholders,
professional advisors such as attorneys and accountants, securities
broker-dealers, investment banking firms, venture capitalists, members of the
financial community and others who may present unsolicited proposals.
Management expects that prior personal and business relationships may lead to
contacts with these various sources.

     Our management will analyze the business opportunities, however, none of
our management are professional business analysts.  (See, Part III, Item 9:
"Directors and Executive Officers . . .") Our management has had limited
experience with acquisitions or mergers of business opportunities and has not
been involved with an initial public offering.  John W. Peters, our President,
has been involved with acquisitions of subsidiaries as president of Earth
Products & Technologies, Inc.  These acquisitions were structured as
stock-for-stock exchanges between Earth Products and other operating
companies.  Due to management's inexperience with acquisitions and mergers,
they may rely on promoters or their affiliates, principal stockholders or
associates to assist in the investigation and selection of business
opportunities.

     Certain conflicts of interest exist or may develop between Cancer Capital
and our officers and directors.  Our management has other business interests
to which they currently devote attention, which include their primary
employment and management of other blank check reporting companies.  They may
be expected to continue to devote their attention to these other business
interests although management time should be devoted to our business.  As a
result, conflicts of interest may arise that can be resolved only through
their exercise of judgement in a manner which is consistent with their
fiduciary duties to us.  In particular, Mr. Peters is a director of other
blank check companies with a structure and a business plan which is identical
to ours and he may in the future be involved with other blank check companies.
In the process of negotiations for an acquisition or merger or determination
of consulting fees related to investigation of a business opportunity, our
management and/or our principal stockholders may consider their own personal
pecuniary benefit or the interests of other blank check companies they are
affiliated with rather than the best interests of Cancer Capital's other
stockholders.

     We presently do not foresee entering into a merger or acquisition
transaction with any business with which our officers or directors are
currently affiliated. We may acquire or merge with companies of which our
management's affiliates or associates have a direct or indirect ownership
interest.  If we determine in the future that a transaction with an affiliate
would be in our best interest we are permitted by Nevada law to enter into
such a transaction if:

     (1)     The material facts regarding the relationship or interest of the
affiliate in the contract or transaction are disclosed or are known to the
Board of Directors.  The board authorizes the contract or transaction by the
affirmative vote of a majority of the disinterested directors, even though the
disinterested directors constitute less than a quorum; or

     (2)     The material facts regarding the relationship or interest of the
affiliate in the contract transaction are disclosed or are known to the
stockholders entitled to vote on the transaction, and the contract or
transaction is specifically approved by vote of the stockholders; or

     (3) The contract or transaction is fair to us at the time it is
authorized, approved or ratified by the Board of Directors or the
stockholders.

     A decision to participate in a specific business opportunity may be made
upon our management's analysis

                                4
<PAGE>


of the quality of the other company's management and personnel, the
anticipated acceptability of the business opportunity's new products or
marketing concept, the merit of its technological changes, the perceived
benefit that it will derive from becoming a publicly held entity, and numerous
other factors which are difficult, if not impossible, to analyze through the
application of any objective criteria.  In many instances, we anticipate that
the historical operations of a specific business opportunity may not
necessarily be indicative of the potential for the future because of the
possible need to substantially shift marketing approaches, significantly
expand operations, change product emphasis, change or substantially augment
management, or make other changes.  We will be dependent upon the owners of a
business opportunity to identify any such problems which may exist and to
implement, or be primarily responsible for, the implementation of required
changes.

     In our analysis of a business opportunity we anticipate that we will
consider, among other things, the following factors:

     (1)   Potential for growth and profitability, indicated by new
technology, anticipated market expansion, or new products;

     (2)   Our perception of how any particular business opportunity will be
received by the investment community and by our stockholders;

     (3)   Whether, following the business combination, the financial
condition of the business opportunity would be, or would have a significant
prospect in the foreseeable future of becoming sufficient to enable our
securities to qualify for listing on a exchange or on a national automated
securities quotation system, such as NASDAQ.

     (4)   Capital requirements and anticipated availability of required
funds, to be provided by us or from operations, through the sale of additional
securities, through joint ventures or similar arrangements, or from other
sources;

     (5)   The extent to which the business opportunity can be advanced;

     (6)   Competitive position as compared to other companies of similar size
and experience within the industry segment as well as within the industry as a
whole;

     (7)   Strength and diversity of existing management, or management
prospect that are scheduled for recruitment;

     (8)   The cost of our participation as compared to the perceived tangible
and intangible values and potential; and

     (9)   The accessibility of required management expertise, personnel, raw
materials, services, professional assistance, and other required items.

     No one of the factors described above will be controlling in the
selection of a business opportunity.  Management will attempt to analyze all
factors appropriate to each opportunity and make a determination based upon
reasonable investigative measures and available data. Potential business
opportunities may occur in many different industries and at various stages of
development.  Thus, the task of comparative investigation and analysis of such
business opportunities will be extremely difficult and complex. Potential
investors must recognize that because of our limited capital available for
investigation and management's limited experience in business analysis, we may
not discover or adequately evaluate adverse facts about the opportunity to be
acquired.

Form of Acquisition

     We cannot predict the manner in which we may participate in a business
opportunity. Specific business

                                5
<PAGE>

opportunities will be reviewed as well as our needs and desires and those of
the promoters of the opportunity.  The legal structure or method deemed by
management to be suitable will be selected based upon our review and our
relative negotiating strength. Such methods may include, but are not limited
to, leases, purchase and sale agreements, licenses, joint ventures and other
contractual arrangements. We may act directly or indirectly through an
interest in a partnership, corporation or other forms of organization.  We may
be required to merge, consolidate or reorganize with other corporations or
forms of business organization. In addition, our present management and
stockholders most likely will not have control of a majority of our voting
shares following a merger or reorganization transaction. As part of such a
transaction, our existing directors may resign and new directors may be
appointed without any vote by our stockholders.

     We likely will acquire our participation in a business opportunity
through the issuance of common stock or other securities.  Although the terms
of any such transaction cannot be predicted, it should be noted that issuance
of additional shares also may be done simultaneously with a sale or transfer
of shares representing a controlling interest by current principal
stockholders.

Competition

     We expect to encounter substantial competition in our effort to locate
attractive opportunities.  Business development companies, venture capital
partnerships and corporations, venture capital affiliates of large industrial
and financial companies, small investment companies, and wealthy individuals
will be our primary competition. Many of these entities will have
significantly greater experience, resources and managerial capabilities than
we do and will be in a better position than we are to obtain access to
attractive business opportunities.  We also will experience competition from
other public "blind check" companies, many of which may have more funds
available for such transactions.

Employees

     We currently have no employees.  Our management expects to confer with
consultants, attorneys and accountants as necessary.  We do not anticipate a
need to engage any full-time employees so long as we are seeking and
evaluating business opportunities.  We will determine the need for employees
based upon the specific business opportunity.


                 ITEM 2: DESCRIPTION OF PROPERTY

     We do not currently own or lease any property.  Until we pursue a viable
business opportunity and recognize income, we will not seek independent office
space.


                    ITEM 3: LEGAL PROCEEDINGS

     We are not a party to any proceedings or threatened proceedings as of the
date of this filing.


   ITEM 4: SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

     We have not submitted a matter to a vote of our shareholders during the
fourth quarter of the 2001 fiscal year.

                                6
<PAGE>

                             PART II

ITEM 5: MARKET PRICE FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

Market, Holders and Dividends

     We have no public market for our common stock as of the date of this
filing.  We have approximately 36 stockholders of record holding 5,150,000
common shares.  Of these shares 525,000 shares are restricted stock as that
term is defined in Rule 144 and 4,625,000 shares are unrestricted shares.  We
have not declared dividends on our common stock and do not anticipate paying
dividends on our common stock in the foreseeable future.

Recent Sales of Unregistered Securities

     The following discussion describes all securities sold by Cancer Capital
within the past three years without registration:

     On June 30, 2000, we issued an aggregate of 200,000 shares valued at
approximately $2,000.  We issued 150,000 shares to John W. Peters and 50,000
shares were issued to Michelle Peters in consideration for services as our
officers. We relied on an exemption from registration provided by Section 4(2)
of the Securities Act for a private transaction not involving a public
distribution.

     On July 10, 2000, we issued 250,000 shares to The Oxford Group for
investment banking services valued at $5,000.  We relied on an exemption from
registration provided by Section 4(2) of the Securities Act for a private
transaction not involving a public distribution.


                    ITEM 6:  PLAN OF OPERATION

     We have experienced losses from inception and for the year ended December
31, 2001 we had $2,000 cash on hand and no current liabilities.  Since
inception, we have primarily financed our operations through the sale of our
common stock, as we have paid for services rendered by management and third
parties with common stock.

     We have no commitments for capital expenditures for the next twelve
months.  During the next twelve months we believe that our current cash needs
can be met by loans from our directors, officers and stockholders based on
informal understandings we have with these individuals.  These understandings
are not written agreements and therefore these persons are not obligated to
provide funds.  We may repay these loans and advancements with cash, if
available, or we may convert them into common stock.

      Our management intends to actively seek business opportunities during
the next twelve months.
In the event we acquire a business opportunity we may incur additional
expenses related to proxy or information statements we must provide to our
stockholders which disclose that company's business operations, management and
financial condition.  In addition, the acquired or merged company will be
subject to these same reporting obligations.

      If we obtain a business opportunity, then it may be necessary to raise
additional capital through the sale of our common stock.  We intend to issue
such stock pursuant to exemptions provided by federal and state securities
laws.  The purchasers and manner of issuance will be determined according to
our financial needs and the available exemptions.  We do not currently intend
to make a public offering of our stock.  We also note that if we issue more
shares of our common stock our shareholders may experience dilution in the
value per share of their common stock.


                   ITEM 7: FINANCIAL STATEMENTS


                                7
<PAGE>




                   Cancer Capital Corporation

                       Financial Statements

                    December 31, 2001 and 2000



<PAGE> 8


                             CONTENTS


Independent Auditor's Report ...............................................3

Balance Sheets..............................................................4

Statements of Operations ...................................................5

Statements of Stockholders' Equity..........................................6

Statements of Cash Flows....................................................7

Notes to the Financial Statements...........................................8





<PAGE> 9



                      CHISHOLM & ASSOCIATES
A Professional           Certified Public Accountants    Office (801)292-8756
Corporation                    P.O. Box 540216              Fax (801)292-8809
                   North Salt Lake, Utah 84054
_____________________________________________________________________________




                   INDEPENDENT AUDITOR'S REPORT



To the Board of Directors and Stockholders
of Cancer Capital Corporation:

We have audited the accompanying balance sheets of Cancer Capital Corporation
(a development stage company) as of December 31, 2001 and 2000 and the related
statements of operations, stockholders' equity and cash flows for the years
ended December 31, 2001 and 2000 and from inception April 11, 1997 through
December 31, 2001.  These financial statements are the responsibility of the
Company's management.  Our responsibility is to express an opinion on these
financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing
standards in the United States of America.  Those standards require that we
plan and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement.  An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements.  An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation.  We believe that our
audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Cancer Capital Corporation
(a development stage company) as of December 31, 2001 and 2000 and the results
of its operations and cash flows for the years ended December 31, 2001 and
2000 and from inception April 11, 1997 through December 31, 2001 in conformity
with generally accepted accounting principles in the United States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern.  The Company has suffered recurring
losses from operations which raises substantial doubt about its ability to
continue as a going concern.  Management's plans in regard to these matters
are described in Note 2.  The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.


/S/ Chisholm & Associates

Chisholm & Associates
North Salt Lake, Utah
January 2, 2002

<PAGE> 10
                    Cancer Capital Corporation
                  (A Development Stage Company)
                          Balance Sheets


                              ASSETS

                                                            December 31
                                                        2001          2000
                                                    ------------ -------------

CURRENT ASSETS

Cash (Note 1)                                       $     2,000  $      2,000
                                                    ------------ -------------

    TOTAL ASSETS                                    $     2,000  $      2,000
                                                    ============ =============


               LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES                                 $         -  $          -

STOCKHOLDERS' EQUITY

Common Stock, $.001 par value; 20,000,000 shares
 authorized; 5,150,000 shares issued and outstanding      5,150         5,150

Additional Paid in Capital                               38,050        38,050

Deficit Accumulated during the development stage        (41,200)      (41,200)
                                                    ------------ -------------

  Total Stockholders' Equity (deficit)                    2,000         2,000
                                                    ------------ -------------

  TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY        $     2,000  $      2,000
                                                    ============ =============









The accompanying notes are an integral part of these financial statements

                               -4-
<PAGE> 11


                    Cancer Capital Corporation
                  (A Development Stage Company)
                     Statement of Operations




                                                              From
                                       For the Years Ended    Inception on
                                           December 31        April 11, 1997
                                       2001           2000    to Dec. 31, 2001
                                  ------------- ------------- ----------------

REVENUES                          $          -  $          -  $           -
                                  ------------- ------------- --------------
EXPENSES

  General & Administrative                   -         7,600         41,200
                                  ------------- ------------- --------------

    Total Expenses                           -         7,600         41,200
                                  ------------- ------------- --------------

Net Loss                          $          -  $     (7,600) $     (41,200)
                                  ============= ============= ==============

Net Loss Per Share                $          -  $          -  $       (0.01)
                                  ============= ============= ==============
Weighted average
  shares outstanding                 5,150,000     4,918,056      4,740,588
                                  ============= ============= ==============










The accompanying notes are an integral part of these financial statements

                               -5-

<PAGE> 12

                    Cancer Capital Corporation
                  (A Development Stage Company)
                Statements of Stockholders' Equity
    From Inception on April 11, 1997 through December 31, 2001

                                                                 Deficit
                                                                 Accumulated
                                                     Additional  During the
                                Common Stock         Paid in     Development
                             Shares       Amount     Capital     Stage
                           ------------- ----------- ----------- -------------
Common stock, issued at
 inception for cash at
 $.001 per share              1,000,000  $    1,000  $        -  $          -

Common stock, issued at
 inception for services
 at $.001 per share             200,000         200           -             -

Common stock issued for
 cash at $.01 per share       3,500,000       3,500      31,500             -

Net (loss) for the year
 ended December 31, 1997              -           -           -       (22,400)
                           ------------- ----------- ----------- -------------

Balance - December 31, 1997   4,700,000       4,700      31,500       (22,400)

Net (loss) for the year
 ended December 31, 1998              -           -           -        (9,900)
                           ------------- ----------- ----------- -------------

Balance - December 31, 1998   4,700,000       4,700      31,500       (32,300)

Net (loss) for the year
 ended December 31, 1999              -           -           -        (1,300)
                           ------------- ----------- ----------- -------------

Balance - December 31, 1999   4,700,000       4,700      31,500       (33,600)

Common stock issued for
 services at $.01 per share     200,000         200       1,800             -

Common stock issued for
 services at $.02 per share     250,000         250       4,750             -

Net (loss) for the year
 ended December 31, 2000              -           -           -        (7,600)
                           ------------- ----------- ----------- -------------

Balance - December 31, 2000   5,150,000       5,150      38,050       (41,200)

Net (loss) for the year
 ended December 31, 2001              -           -           -             -
                           ------------- ----------- ----------- -------------

Balance - December 31, 2001   5,150,000  $    5,150  $   38,050  $    (41,200)
                           ============= =========== =========== =============








The accompanying notes are an integral part of these financial statements

                               -6-


<PAGE> 13

                    Cancer Capital Corporation
                  (A Development Stage Company)
                     Statement of Cash Flows

<PAGE>
<TABLE>
<CAPTION>
                                                                   From
                                          For the Years Ended      Inception on
                                              December 31          April 11, 1997
                                       --------------------------- Through
                                          2001           2000      December 31,2001
                                       ------------- ------------- ----------------
<S>                                    <C>           <C>           <C>
Cash Flows from Operating Activities

  Net Loss                             $          -  $     (7,600) $      (41,200)
  Adjustments for non-cash items:
   Shares issued for services                     -         7,000           7,200
                                       ------------- ------------- ----------------
  Net Cash Provided (Used) by
   Operating Activities                           -          (600)        (34,000)
                                       ------------- ------------- ----------------

Cash Flows from Investing Activities:             -             -               -
                                       ------------- ------------- ----------------
  Net Cash Provided (Used) in
    Investing Activities                          -             -               -
                                       ------------- ------------- ----------------
Cash Flows from Financing Activities:
  Issued common stock for cash                    -             -          36,000
                                       ------------- ------------- ----------------
  Net cash Provided by
   Financing Activities                           -             -          36,000
                                       ------------- ------------- ----------------

Increase (Decrease) in Cash                       -          (600)          2,000

Cash beginning of period                          -         2,600               -
                                       ------------- ------------- ----------------

Cash end of period                     $          -  $      2,000  $        2,000
                                       ============= ============= ================

Supplemental Cash Flow Information:

  Cash Paid For:
    Interest                           $          -  $          -  $            -
    Income Taxes                       $          -  $          -  $            -


NonCash Financing Activities

  During 1997, 200,000 shares of common stock were issued at $.001 per
  share for services

  During 2000, 200,000 and 250,000 shares of common stock were issued
  for services at $.01 and $.02 per share, respectively



The accompanying notes are an integral part of these financial statements

                               -7-

</TABLE>
<PAGE> 14



                    Cancer Capital Corporation
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2001 and 2000

NOTE 1 - Summary of Significant Accounting Policies

         a.  Organization & Consolidation Policy

             Cancer Capital Corporation  (the Company), was incorporated April
11, 1997 under the laws of the State of Nevada.   The Company was originally
formed for the purpose of developing an alternative medical waste treatment
system.  However, the Company in December 1997 abandoned this purpose and has
since been inactive.  The Company has never commenced any significant
activities or secured operations.  The Company is currently searching for
other business opportunities and is in the development stage according to
Financial Accounting Standards Board Statement No. 7.

         b.  Accounting Method

             The Company recognizes income and expense on the accrual basis of
accounting.

         c.  Earnings (Loss) Per Share

                                      Income (loss)  Shares       Per Share
                                       (Numerator) (Denominator)    Amount
                                       ------------ ------------ ------------
For the year ended December 31, 2001:

Basic EPS
 Income (loss) to common stockholders  $         -    5,150,000  $     (0.00)
                                       ============ ============ ============


For the year ended December 31, 2000:

Basic EPS
 Income (loss) to common stockholders   $  ( 7,600)   4,918,056  $     (0.00)
                                        =========== ============ ============

From inception on April 11, 1997 to
  December 31, 2001:

Basic EPS
  Income (loss) to common stockholders  $  (41,200)   4,740,588  $     (0.01)
                                        ============ =========== ============

     The computation of earnings per share of common stock is based on the
weighted average number of shares outstanding at the date of the financial
statements.

         d.  Cash and Cash Equivalents

             The Company considers all highly liquid investments with
maturities of three months or less to be cash equivalents.

                               -8-

<PAGE> 15

                    Cancer Capital Corporation
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2001 and 2000

NOTE 1 - Summary of Significant Accounting Policies (continued)

         e.  Provision for Income Taxes

             No provision for income taxes have been recorded due to net
operating loss carryforwards totaling approximately $41,200 will be offset
against future taxable income.  These NOL carryforwards began to expire in the
year 2017  No tax benefit has been reported in the financial statements
because the Company believes there is a 50% or greater chance the carryforward
will expire unused.

             Deferred tax asset and the valuation account is as follows as
December 31, 2001 and 2000:


                                                           December 31,
                                                      2001           2000
                                                   ------------- ------------
       Deferred tax asset:
         NOL carryforward                          $      6,180  $     6,180

         Valuation allowance                          (   6,180)   (   6,180)
                                                   ------------- ------------

                                                   $          -  $         -
                                                   ============= ============

         f.  Use of estimates

         The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period.  Actual results could differ from those estimates.

NOTE 2 - Going Concern

         The accompanying financial statements have been prepared assuming
that the Company will continue as a going concern.  The Company has no assets
and has had recurring operating losses for the past several years and is
dependent upon financing to continue operations.  The financial statements do
not include any adjustments that might result from the outcome of this
uncertainty.  It is management's plan to find an operating company to merge
with, thus creating necessary operating revenue.

NOTE 3 - Development Stage Company

         The Company is a development stage company as defined in Financial
Accounting Standards Board Statement No. 7.  It is concentrating substantially
all of its efforts in raising capital and defining its business operation in
order to generate significant revenues.


                               -9-
<PAGE> 16


      ITEM 8: CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS

     We have not had a change in or disagreement with our principal
independent accountant during the past two fiscal years.


                             PART III

ITEM 9: DIRECTORS AND EXECUTIVE OFFICERS; COMPLIANCE WITH SECTION 16(a)

     Our executive officers and directors and their respective ages, positions
and term of office are set forth below.  Biographical information for each of
those persons is also presented below.  Our bylaws require two directors who
serve for terms of one year or until they are replaced by a qualified
director.  Our executive officers are chosen by our Board of Directors and
serve at its discretion.  John and Michelle Peters are married.

                                                         Director or
Name              Age  Position Held                     Officer Since
----------------  ---- --------------------------------- ---------------

John W. Peters     50  President and Director            April 11, 1997

Michelle Peters    49  Secretary/Treasurer and Director   April 11, 1997


John W. Peters.   Mr. Peters has served as our President and a Director since
our inception.  Since July 1999 he has been the manager of Development
Specialties, Inc. a property management company.  Since 1995 to the present he
has been President and Chairman of the Board of Earth Products and
Technologies, Inc, a reporting company.  He is a director of the following
blank check reporting companies: Bingham Canyon Corporation and Skinovation
Pharmaceutical, Inc.  Prior business experience includes Operations Manager
for Earth Products, President and Executive Officer of Certified Environmental
Laboratories, Inc. and Vice President of Sales and Marketing for Comco
Communications Corp. in California.  Mr. Peters studied business
administration at Long Beach Community College and California Polytechnic
State University in San Louis Obispo, California.

Michelle Peters.  Mrs. Peters has served as our Secretary/Treasurer and as a
Director since our inception.  From 1997 to the present she has been employed
as a legal secretary for Thompson Hazer and Scoussen located in Salt Lake
City, Utah.  She was employed as a legal secretary by Parsons Behle & Latimer
from 1993 to 1997.  Mrs. Peters has 29 years of experience in the legal
profession as a legal secretary, paralegal and office administrator.

Section 16(a) Beneficial Ownership Reporting Compliance

     Section 16(a) of the Securities Exchange Act of 1934 requires our
directors, executive officers and persons who own more than ten percent of a
registered class of our equity securities, to file with the Securities and
Exchange Commission initial reports of ownership and reports of changes in
ownership of our common stock. Officers, directors and greater than
ten-percent beneficial owners are required by SEC regulations to furnish us
with copies of all Section 16(a) reports they file.  We believe that no
reports were required to be filed during the 2001 fiscal year based upon the
lack of such forms furnished to us during the fiscal year ended December 31,
2001 and representations from known reporting persons that Forms 5 were not
required.


                 ITEM 10: EXECUTIVE COMPENSATION

     Our named executive officers have not received any cash compensation,
bonuses, stock appreciation rights, long term compensation, stock awards or
long-term incentive rights in excess of $100,000 during the past three fiscal
years.  John W. Peters, who acts in the capacity similar to Chief Executive
Officer did not receive any

                                17
<PAGE>


compensation during the 2001 fiscal year; however, in June 2000 we issued
150,000 common shares valued at $1,500 to Mr. Peters for services rendered to
Cancer Capital.  We have not entered into employment contracts with our
executive officers and their compensation, if any, will be determined at the
discretion of our Board of Directors.

Compensation of Directors

     We do not have any standard arrangement for compensation of our directors
for any services provided as director, including services for committee
participation or for special assignments.


ITEM 11: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

     The following table sets forth the beneficial ownership of our
outstanding common stock by our management and each person or group known by
us to own beneficially more than 5% of our outstanding common stock.
Beneficial ownership is determined in accordance with the rules of the SEC and
generally includes voting or investment power with respect to securities.
Except as indicated by footnote, the persons named in the table below have
sole voting power and investment power with respect to all shares of common
stock shown as beneficially owned by them.  The percentage of beneficial
ownership is based upon 5,150,000 shares of common stock outstanding as of
February 27, 2002.


                    CERTAIN BENEFICIAL OWNERS

                                       Common Stock Beneficially Owned
                                       ---------------------------------
Name and Address of         Number of Shares of
Beneficial Owners           Common Stock              Percentage of Class
----------------------     -----------------------    -------------------
M. Jeanne Ball                   400,000                   7.8%
6071 Aries Drive
Salt Lake City, Utah 84118

Anita Patterson
588 NO West Capital
Salt Lake City, Utah 84103       400,000                   7.8%


                            MANAGEMENT

                                          Common Stock Beneficially Owned
                                          -------------------------------
Name and Address of          Number of Shares of
Beneficial Owners            Common Stock             Percentage of Class
-------------------         ------------------------  -------------------

John W. Peters                   650,000                   12.6%
525 South 300 East
Salt Lake City, Utah 84111

Michelle Peters                  450,000                    8.7%
525 South 300 East
Salt Lake City, Utah 84111

All executive officers and
directors as a group            1,100,000                  21.4%



                                18
<PAGE>

     ITEM 12: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

     The following information summarizes transactions we have either engaged
in during the last two fiscal years or propose to engage in involving our
executive officers, directors, more than 5% stockholders, or immediate family
members of such persons.

     On June 30, 2000 we issued an aggregate of 200,000 common shares to John
and Michelle Peters in consideration for their services as our officers.  John
received 150,000 shares valued at $1,500 and Michelle received 50,000 shares
valued at $500.  This transaction was negotiated between related parties
without "arms length" bargaining and as a result, the terms of this
transaction may be different than transactions between unrelated parties.


ITEM 13: EXHIBITS AND REPORTS ON FORM 8-K

Exhibits

Exhibit
Number          Description
---------       ------------

3.1     Articles of Incorporation (Incorporated by reference to exhibit 3.1 to
        Form 10-SB, filed February 20, 2001)

3.2     Bylaws of Cancer Capital Corp. (Incorporated by reference to exhibit
        3.2 to Form 10-SB, filed February 20, 2001)



Reports on 8-K

     None.


                                19
<PAGE>
<PAGE>
                            SIGNATURE


     In accordance with Section 13 or 15(d) of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

               3/20/02
     Date________________     Cancer Capital Corp.



                              By: _ /s/ John W. Peters
                                  ----------------------------------------
                                    John W. Peters, President and Director



     In accordance with the Exchange Act, this report has been signed below by
the following person on behalf of the registrant and in the capacities and on
the dates indicated.




             3/20/02
     Date ________________    By:  /s/ Michele Peters
                                  -----------------------------------------
                                   Michelle Peters, Secretary/Treasurer and
                                   Director